Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Share News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.585
Bid: 0.57
Ask: 0.60
Change: 0.01 (1.74%)
Spread: 0.03 (5.263%)
Open: 0.575
High: 0.00
Low: 0.00
Prev. Close: 0.575
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Provexis Remains Positive On Outlook As Pretax Loss Widens Slightly

Tue, 22nd Dec 2015 11:22

LONDON (Alliance News) - Provexis PLC on Tuesday said it remains positive about its outlook for its financial second half and beyond, as it reported a slightly widened pretax loss for the first half amid a continued marketing drive for its food ingredient Fruitflow.

Shares in Provexis were down 14% at 0.297 pence Tuesday morning.

For the half year to end-September the company reported a pretax loss of GBP228,447, widened slightly from GBP207,542, as a rise in revenue to GBP40,908 from GBP8,261 was offset by higher research and development costs.

During the half year Provexis' partner DSM Nutritional Products continued to roll-out Fruitflow with its customers, which helped drive revenue. Additionally, in June, Provexis agreed "significantly enhanced" financial terms on its agreement with DSM for Fruitflow, which it said will boost its ongoing profit share from the agreement going forward.

Following the half-year end, Provexis inked a deal with the University of Oslo to undertake further research into the relationship between Fruitflow and blood pressure regulation. Key results from the first stage of this work have been "very encouraging", the company said, and it is now proceeding on to the second stage.

Additionally, Provexis has been working towards launching a dietary supplement containing Fruitflow and Omega-3, which it expects to provide it with an additional revenue and profit stream. It plans to launch this product "as soon as possible".

"The first six months of the year have seen a number of very positive developments for the business, and with the company's low operational costs we are well positioned to drive value for shareholders. We remain positive about the outlook for the business for the second half of the year and beyond," Provexis said in a statement.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
3 Dec 2009 08:49

Small caps round-up: Landore Resources, TXO, Aortech...

Shares in Landore Resources jumped after the Canadian miner said it made a 'significant gold discovery' in its Junior Lake property in the province of Ontario. Shares in Texas-focused oil and gas firm TXO slumped after it said oil production in the six months to September 30 fell to 13,221 barrels

Read more
3 Nov 2009 12:16

Small cap round-up: Provexis, Puricore, Sirius, Sopheon, Spiritel

Food technology group Provexis says it has been told that the European Commission review into the health claim wording for its Fruitflow anti-thrombatic technology for use on consumer products is now in "an advanced stage". Puricore's third quarter sales rose 25% to $10.8m, with the nine month tot

Read more
11 Aug 2009 09:30

Provexis surges on Crohn's disease trial

Provexis, the life-science business, has begun a clinical trial for its NSP#3G plantain medical food for Crohn's disease patients. "With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-de

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.